Business Context and Reporting Period
Company: Broadwind, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2025
Reporting Period: Event date of February 4, 2025
Broadwind, Inc. filed this report to disclose the entry into a material definitive agreement regarding its Section 382 Rights Agreement. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BWEN.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and shareholder rights modifications.
Material Changes Versus Prior Period
The Board of Directors approved a Fourth Amendment to the Section 382 Rights Agreement, resulting in the following material changes:
- Purchase Price Adjustment: The purchase price for each one-thousandth of a share of Series A Junior Participating Preferred Stock increased from $7.26 to $7.70.
- Expiration Date Extension: The Final Expiration Date was extended from February 22, 2025, to February 22, 2028.
- Conditional Exercisability: The Rights will no longer be exercisable if stockholders do not approve the Fourth Amendment at the 2025 Annual Meeting of Stockholders.
Guidance, Outlook, and Management Commentary
Purpose of Amendment: Management states the amendment was adopted to preserve the long-term value of the Company's net operating loss (NOL) carry-forwards for U.S. federal income tax purposes and other tax benefits.
Acquisition Context: The filing explicitly states the amendment was not adopted in response to any effort to acquire control of the Company.
Risks and Contingencies: The continued validity of the Rights Agreement is contingent upon stockholder approval at the upcoming 2025 Annual Meeting. Without approval, the Rights will cease to be exercisable.
Important Facts for Investor Verification
- Verify the outcome of the 2025 Annual Meeting of Stockholders regarding the approval of the Fourth Amendment.
- Confirm the impact of the extended expiration date (2028) on the company's poison pill defense strategy.
- Review the full text of the Fourth Amendment (Exhibit 4.1) for specific terms regarding the rights agent, Equiniti Trust Company.
- Monitor future filings for any updates on the utilization of net operating loss carry-forwards.